成都先導藥物開發(fā)股份有限公司（上海證券交易所股票代碼：688222.SH，股票名稱：成都先導）致力于打造國際領先的創(chuàng)新型生物醫(yī)藥企業(yè)，總部位于中國成都，在英國劍橋、美國休斯頓設有子公司。公司聚焦小分子及核酸新藥的發(fā)現(xiàn)與優(yōu)化，著力打造了國際領先的DNA編碼化合物庫技術（DEL）平臺，并拓展了基于分子片段和三維結構信息的藥物設計技術（FBDD/SBDD）、基于寡核苷酸的藥物研發(fā)技術（OBT）和靶向蛋白降解技術（TPD）的核心技術平臺；同時，公司正在建設DEL+AI+自動化DMTA（設計-合成-測試-分析）分子優(yōu)化能力平臺，以期加速臨床前候選藥物發(fā)現(xiàn)及優(yōu)化過程。通過新藥研發(fā)服務、不同階段在研項目轉讓以及遠期的藥物上市等多元化的商業(yè)模式，成都先導與全球數(shù)百家制藥公司、生物技術公司、化學公司、基金會以及科研機構建立了合作。目前，公司有多個內部新藥項目處于臨床及臨床前不同階段。

獲取更多信息，請致電+86-28-85197385，+1-508-840-9646或訪問www.hitgen.com。

媒體查詢：media@hitgen.com

投資者咨詢：investors@hitgen.com

商務開發(fā)：bd@hitgen.com

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.

For media inquiries: media@hitgen.com

For investor inquiries: investors@hitgen.com

For business development: bd@hitgen.com